MiMedx Group PT Raised to $6.50 (MDXG)
Analysts at Canaccord Genuity hoisted their price objective on shares of MiMedx Group (NASDAQ:MDXG) from $6.00 to $6.50 in a research report issued to clients and investors on Thursday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 22.64% from the stock’s previous close.
Shares of MiMedx Group (NASDAQ:MDXG) traded down 0.75% on Thursday, hitting $5.30. The stock had a trading volume of 379,549 shares. MiMedx Group has a 1-year low of $2.31 and a 1-year high of $7.73. The stock has a 50-day moving average of $4.67 and a 200-day moving average of $5.90. The company’s market cap is $510.8 million.
MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.00 earnings per share (EPS) for the quarter. The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $15.23 million. The company’s revenue for the quarter was up 102.5% on a year-over-year basis. On average, analysts predict that MiMedx Group will post $-0.02 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on MDXG. Analysts at Northland Capital Partners cut their price target on shares of MiMedx Group from $7.00 to $5.00 in a research note to investors on Friday, September 6th. They now have an “outperform” rating on the stock. Separately, analysts at Lake Street Capital initiated coverage on shares of MiMedx Group in a research note to investors on Tuesday, August 20th. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a buy rating, MiMedx Group currently has a consensus rating of “Buy” and a consensus price target of $5.38.
MiMedx Group, Inc is a development-stage company. The Company is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.